Korean Rosuvastatin Effectiveness Study in nondiabetic metabolic syndrome

Exclusion Criteria

• - History of known diabetes mellitus
• - Use of anti-hyperglycaemic medication.
• - History of serious or hypersensitivity reactions to HMG-CoA reductase inhibitors, in particular history of myopathy.
• - No CHD or CHD Risk Equivalents and 0-1 Risk factors and Framingham 10-Year risk is <10%.
• - History of heterozygous or homozygous familial hypercholesterolaemia or known type III hyperlipoproteinaemia (familial dysbetalipoproteinaemia).
• - Active arterial disease such as unstable angina pectoris, myocardial infarction, transient ischaemic attack (TIA), cerebrovascular accident (CVA), coronary artery bypass surgery (CABG) or angioplasty within 2 months prior to entry in the dietary lead in period
• - Uncontrolled hypothyroidism defined as thyroid stimulating hormone (TSH) > 1.5 times the upper limit of normal (ULN) at Visit 2 or subjects whose thyroid replacement therapy was initiated within 3 months of entry into dietary lead-in phase.
• - Current active liver disease (alanine aminotransferase [ALT] > 2 x ULN) or severe hepatic impairment.
• - Unexplained serum CK >3 times ULN (e.g. not due to recent trauma, intramuscular injections, heavy exercise, etc).
• - Serum creatinine > 176 umol/L (2.0 mg/dL)
• - History of alcohol, or drug, abuse or both.